Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3614042
Max Phase: Preclinical
Molecular Formula: C14H11N7S
Molecular Weight: 309.36
Molecule Type: Small molecule
Associated Items:
ID: ALA3614042
Max Phase: Preclinical
Molecular Formula: C14H11N7S
Molecular Weight: 309.36
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Cc1ccccc1-c1csc(-n2cc(-c3nnn[nH]3)cn2)n1
Standard InChI: InChI=1S/C14H11N7S/c1-9-4-2-3-5-11(9)12-8-22-14(16-12)21-7-10(6-15-21)13-17-19-20-18-13/h2-8H,1H3,(H,17,18,19,20)
Standard InChI Key: ZKUSGCJJBWRATE-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 309.36 | Molecular Weight (Monoisotopic): 309.0797 | AlogP: 2.48 | #Rotatable Bonds: 3 |
Polar Surface Area: 85.17 | Molecular Species: ACID | HBA: 7 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 3.98 | CX Basic pKa: 0.65 | CX LogP: 3.23 | CX LogD: 1.62 |
Aromatic Rings: 4 | Heavy Atoms: 22 | QED Weighted: 0.63 | Np Likeness Score: -2.58 |
1. Duan LM, Yu HY, Li YL, Jia CJ.. (2015) Design and discovery of 2-(4-(1H-tetrazol-5-yl)-1H-pyrazol-1-yl)-4-(4-phenyl)thiazole derivatives as cardiotonic agents via inhibition of PDE3., 23 (18): [PMID:26319621] [10.1016/j.bmc.2015.08.002] |
Source(1):